MX2025001036A - Composicion farmaceutica que comprende un inhibidor de kras g12d - Google Patents

Composicion farmaceutica que comprende un inhibidor de kras g12d

Info

Publication number
MX2025001036A
MX2025001036A MX2025001036A MX2025001036A MX2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
kras
inhibitor
present disclosure
disclosure relates
Prior art date
Application number
MX2025001036A
Other languages
English (en)
Inventor
Ruilin Sha
Ziqing Duan
Haifeng Wang
Xinyong Tong
Pingping Wang
Biao Feng
Bin Wang
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2025001036A publication Critical patent/MX2025001036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a una composición farmacéutica que comprende un inhibidor de KRAS G12D. En particular, la presente descripción se refiere a una composición farmacéutica, que comprende un compuesto representado por la fórmula I o una sal farmacéuticamente aceptable del mismo, y un lípido. La composición farmacéutica puede aplicarse mejor clínicamente. (ver Fórmula).
MX2025001036A 2022-07-29 2025-01-24 Composicion farmaceutica que comprende un inhibidor de kras g12d MX2025001036A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210909959 2022-07-29
CN202211642769 2022-12-20
PCT/CN2023/109901 WO2024022507A1 (zh) 2022-07-29 2023-07-28 一种包含kras g12d抑制剂的药物组合物

Publications (1)

Publication Number Publication Date
MX2025001036A true MX2025001036A (es) 2025-03-07

Family

ID=89705462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001036A MX2025001036A (es) 2022-07-29 2025-01-24 Composicion farmaceutica que comprende un inhibidor de kras g12d

Country Status (9)

Country Link
EP (1) EP4563151A4 (es)
JP (1) JP2025524799A (es)
KR (1) KR20250037564A (es)
CN (1) CN119384279A (es)
AU (1) AU2023314335A1 (es)
CA (1) CA3261035A1 (es)
MX (1) MX2025001036A (es)
TW (1) TW202408536A (es)
WO (1) WO2024022507A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968570B2 (en) * 2013-01-14 2018-05-15 Chemo-Enhanced Llc Compositions and methods for treating cancer
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN112745335B (zh) * 2019-10-30 2024-08-30 武汉誉祥医药科技有限公司 一种三并杂环化合物及其用途
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021203768A1 (zh) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
WO2022017339A1 (zh) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
MX2023015533A (es) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
CN117677624A (zh) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2023314335A1 (en) 2025-02-27
EP4563151A4 (en) 2025-11-05
KR20250037564A (ko) 2025-03-17
CA3261035A1 (en) 2025-04-04
TW202408536A (zh) 2024-03-01
CN119384279A (zh) 2025-01-28
EP4563151A1 (en) 2025-06-04
JP2025524799A (ja) 2025-08-01
WO2024022507A1 (zh) 2024-02-01

Similar Documents

Publication Publication Date Title
TW200608972A (en) Aryl-pyridine derivatives
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
UA94052C2 (uk) Похідні піридазину
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
MX2010005824A (es) Derivados de aminotiazol.
TNSN06377A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
IN2012DN03337A (es)
DE602005013793D1 (de) Thiazolderivate mit vap-1-hemmender wirkung
MX2024007242A (es) Lipido y composicion utilizada para la administracion.
PH12023552774A1 (en) Nek7 inhibitors
MX2009009849A (es) Derivados de piridazinona sustituida con piperazina utiles como inhibidores de glucano sintasa.
SG2013013339A (en) N3 alkylated benzimidazole derivatives as mek inhibitors
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
ZA202401684B (en) Novel parp7 inhibitor and use thereof
WO2020063696A8 (zh) 胺基脲敏感性胺氧化酶抑制剂制备及其应用
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
PH12022551241A1 (en) Egfr inhibitors
MX2009003169A (es) Derivados de sulfonamida.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2023012004A (es) DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA.
UY27930A1 (es) Derivados de tiazol
MY147188A (en) Substituted imidazole compounds as ksp inhibitors